InvestorsHub Logo
icon url

IgnoranceIsBliss

12/08/18 9:46 AM

#166223 RE: venus537 #166222

Independent thought has become a genuine rarity in this era

We are spoon fed (really, force fed) so much faulty information in sound bites, and people have become so lazy, that you have to smash them over the head to consider anything new that takes any mental effort

We're an army of robots here in 2018 -- the perfect consumption lemmings

The upside of that is that once you get momentum going, it's hard to stop, for pretty much the same reason
icon url

sharinky

12/08/18 9:46 AM

#166224 RE: venus537 #166222

In many cases it is not the doctors, it is the insurance plans and the pharmacists. Prior Authorizations will require generic lovaza first based on the old logic that it was probably almost as good. Many of those generic lovaza script may have also been in the Medicaid populations.

This is where Amarin Managed Care department with the new data needs to come in. I am sure if they have not already they will be sending packages with new data to insurance carriers. Of course, many will stall until FDA approval.
icon url

tmac20

12/08/18 9:48 AM

#166225 RE: venus537 #166222

It is worse than that Venus - It's like they just did a study for fish oil in general. I can guarantee if I went to my doctor and asked for this, she would skim over some literature and say "why don't you just take some over the counter fish oil pills". You are correct, there is going to be a lot of companys using Amarin's hard work (and money) for the R-I trial to promote their own stuff. Unless Amarin can come out full bore and get to these doctors before every other company, it is going to be twice as hard to convince them that Amarin is different. Time is of the essence here and I'm not sure management is aware of that.
icon url

staccani

12/08/18 11:31 AM

#166237 RE: venus537 #166222

Well, I wouldn't mind if Vascepa gets that 65% of the expected global Omega 3 market by 2025 ($57B). In fact , after V results, it may well be much higher than $57B, as Vascepa is set to drive a faster growth

https://www.prnewswire.com/news-releases/omega-3-supplements-market-size-worth-usd-57-06-billion-by-2025-hexa-research-832514526.html
icon url

Don'tDrinkTheKoolAid

12/08/18 11:48 AM

#166240 RE: venus537 #166222

I know a guy who had 2 stents put in at the Cleveland Clinic. Cholesterol off the charts 4o mg lipitor started now down to 30mg. Blood pressure 160/95 lowest reading. DR told him to take FISH OIL! I said you need Vascepa nah I don't need that. My Dr said fish oil. I said but that doesn't work. Then why did the best heart clinic the Cleveland clinic tell me to take FISH OIL!

I sent him info on Vascepa tried to explain that fish oil doesn't work. Also told him you should be taking COq10 he said why do I need that? My Dr. never said anything about it.

He said he will ask his Dr. about Vascepa but doesn't think it's any better than fish oil.
This is the thinking we are up against. I was rolling my eyes thinking OH no NOT the Cleveland Clinic no way will they RX Vascepa it will be Dr. Nissen what ever he's backing.